Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Health System - Encinitas — Encinitas, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in California: - Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Cedars Sinai Medical Center — Los Angeles, California
- Mattel Children's Hospital UCLA — Los Angeles, California
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- UCLA University of California Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- University of California Irvine — Orange, California
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in California: - University of California, San Diego — La Jolla, California
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
- University of California, Los Angeles — Los Angeles, California
- St. Joseph Hospital — Orange, California
- University of California, San Francisco — San Francisco, California
Phase 3 Recruiting Industry
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05566795
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County Main Campus - Orange — Orange, California
- Packard Children's Hospital Stanford — Palo Alto, California
- UCSF Benioff Children's Hospital — San Francisco, California
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in California: - University of Southern California — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Stanford Cancer Institute — Palo Alto, California
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Sponsor: Hoffmann-La Roche
NCT ID: NCT05503264
Sites in California: - UC San Diego — La Jolla, California
- Hoag Memorial Hospital — Newport Beach, California
- UCSF- Multiple Sclerosis Centre — San Francisco, California
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in California: - Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Epic Care-Dublin — Dublin, California
- Bay Area Breast Surgeons Inc — Emeryville, California
- Epic Care Partners in Cancer Care — Emeryville, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in California: - Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Cedars Sinai Medical Center — Los Angeles, California
- UCSF Benioff Children's Hospital Oakland — Oakland, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 2 Recruiting Academic/Other
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Sponsor: Giselle Sholler
NCT ID: NCT04696029
Sites in California: - UCSF Benioff Children's Hospital Oakland — Oakland, California
- Rady Children's Hospital — San Diego, California
- Stanford University — Stanford, California
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in California: - City of Hope--Duarte — Duarte, California
- Cancer & Blood Research Center, LLC — Los Alamitos, California
- Univ. of California Los Angeles — Los Angeles, California
- FOMAT Medical Research (Network) — Oxnard, California
- Scripps Health — San Diego, California
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Research…
Sponsor: Diakonos Oncology Corporation
NCT ID: NCT06805305
Sites in California: - City of Hope — Duarte, California
- HOAG — Newport Beach, California
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in California: - University of California, Irvine — Irvine, California
- University of California Los Angeles — Los Angeles, California
- University of California at San Francisco — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Sponsor: VBI Vaccines Inc.
NCT ID: NCT03382977
Sites in California: - University of California, Irvine — Irvine, California
- University of California, San Diego — La Jolla, California
- University of California, Los Angeles Neuro-Oncology Program — Los Angeles, California
- Stanford — Stanford, California
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in California: - Providence Medical Foundation — Fullerton, California
- California Research Institute — Los Angeles, California
Phase 2 Recruiting Academic/Other
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in California: - Lucille Packard Children's Hospital Stanford — Palo Alto, California
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in California: - Cedars Sinai Medical Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in California: - Precision NextGen Oncology — Beverly Hills, California
- OPN Healthcare, Inc — Glendale, California
- University of Southern California — Los Angeles, California
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in California: - Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
Phase 2 Recruiting Academic/Other
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard …
Sponsor: Cedars-Sinai Medical Center
NCT ID: NCT05708352
Sites in California: - Cedars-Sinai Medical Center — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- Pacific Neuroscience Institute / Saint John's Cancer Institute — Santa Monica, California
Phase 1, Phase 2 Recruiting Academic/Other
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate …
Sponsor: University of California, San Francisco
NCT ID: NCT06504381
Sites in California: - University of Southern California — Los Angeles, California
- University of California, San Diego — San Diego, California
- University of California — San Francisco, California
Phase 2 Recruiting Industry
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. The …
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06061809
Sites in California: - Chan Soon-Shiong Institute for Medicine (CSSIFM) — El Segundo, California
- Providence Medical Foundation — Fullerton, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
Phase 2 Recruiting Academic/Other
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…
Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in California: - University of California, San Francisco — San Francisco, California